New milestone for ALK-positive lung cancer treatment
MILAN (ITALPRESS) – Seven years after the start, the CROWN study confirms that lorlatinib offers the longest-lasting free survival of progression (PFS) in non-small cell lung cancer (NSCLC) ALK-advanced device. The international phase 3 trial, which rated lorlatinib – third-generation […]
New milestone for ALK-positive lung cancer treatment Read More »










